Hungarian drug maker Gedeon Richter on Tuesday said it entered into a partnership with Japan's Mochida Pharmaceutical on the development and marketing of Richter's biosimilar product portfolio.
Under the agreement, Mochida will contribute to the cost of developing Richter's biosimilar products and receive exclusive marketing and distribution rights for the product portfolio in Japan under Mochida trademarks. Richter will also get payments linked to the fulfillment of certain regulatory criteria as well as royalties following the launch of the products in Japan.
Richter is responsible for developing the biosimilar product line, but Mochida will participate if “special market related development criteria” are required in Japan.
Richter expects to launch its biosimilar product portfolio worldwide after 2015. (MTI-Econews)